Merck's Pipeline Promises Face Execution Reality as Keytruda Cliff Approaches

What happened

A recent Zacks article highlights Merck's reliance on new products and pipeline expansion to mitigate Keytruda's 2028 loss-of-exclusivity, projecting $70B in potential commercial opportunities by the mid-2030s. However, the DeepValue report notes that while Keytruda sales grew 7% YoY to $31.7B in FY2025, diversification through assets like WINREVAIR and CAPVAXIVE remains early-stage and insufficient to offset near-term risks. Merck's reorganization into separate oncology and non-oncology units aims to accelerate launch execution, but concrete evidence in SEC filings, such as segment reporting, is still absent. Critical headwinds include a preliminary injunction against subcutaneous Keytruda in Germany and the need for CD388's Phase 3 trial to advance without design setbacks, threatening pipeline timelines. Overall, the optimistic pipeline narrative must be validated by operational milestones, as legal and execution challenges pose tangible threats to Merck's post-LOE strategy.

Implication

Merck's $70B pipeline potential is highly speculative, relying on flawless execution of ~80 Phase 3 trials with no guarantee of commercial success. The reorganization's effectiveness must be proven through upcoming SEC filings that detail segment-level accountability and faster approval-to-launch cadence. Legal disputes over subcutaneous Keytruda, such as the Germany injunction, could expand and undermine lifecycle defense strategies in key markets. CD388's Phase 3 interim analysis in 2026 is a critical test for the Cidara acquisition, with any delays increasing financial drag and diversification uncertainty. Without demonstrable progress, Merck remains vulnerable to Gardasil's decline and intensifying LOE concerns, capping near-term upside.

Thesis delta

The Zacks article reinforces Merck's pipeline optimism but does not shift the DeepValue thesis, which already emphasizes that execution proof is needed amidst risks. No material change: the stock's potential still hinges on observable reorg outcomes, CD388 progress, and legal resolution, with investor patience wearing thin on strategic messaging.